Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,033

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Open access
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., Winer, E.·2017·Annals of Oncology
DOI 10.1093/annonc/mdw544
Open this paper in CoChat — free account

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvement in median overall survival [5, 6].

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw544

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 51

  1. Howlader, 2016, SEER Cancer Statistics Review, 1975–2013
  2. Sundquist, 2010, Trends in survival in metastatic breast, Cancer Eur J Cancer, 8, 191., 10.1016/S1359-6349(10)70474-2 · DOI
  3. Chia, 2007, The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer, Cancer, 110, 973, 10.1002/cncr.22867 · DOI · Paper page
  4. Schnipper, 2015, American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options, J Clin Oncol, 33, 2563, 10.1200/JCO.2015.61.6706 · DOI · Paper page
  5. Cardoso, 2012, 1st International consensus guidelines for advanced breast cancer (ABC1), The Breast, 21, 242, 10.1016/j.breast.2012.03.003 · DOI · Paper page
  6. Key components of Patient Centered Care, adapted from Levit L et al. Delivering high-quality cancer care: charting a new course for a system in crisis. National Academy of Science: Institute of Medicine, The National Academies, 2013; 20,1. 3 p.3.4–3.7.
  7. Cardoso, 2016, Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: results from the count us, know us, join us and here & now surveys, The Breast, 28, 5, 10.1016/j.breast.2016.04.004 · DOI
  8. Karlsson, 2014, Breast cancer during follow-up and progression – a population based cohort on new cancers and changed biology, Eur J Cancer, 50, 2916, 10.1016/j.ejca.2014.08.014 · DOI
  9. Thompson, 2010, Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS), Breast Cancer Res, 12, R92, 10.1186/bcr2771 · DOI · Paper page
  10. Penault-Llorca, 2013, Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status, Breast, 22, 200, 10.1016/j.breast.2012.12.004 · DOI
  11. Schrijver, 2016, Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer, Mod Pathol, 10.1038/modpathol.2016.116 · doi:10.1038/modpathol.2016.116
  12. André, 2014, Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Lancet Oncol, 15, 267, 10.1016/S1470-2045(13)70611-9 · DOI · Paper page
  13. Badwe, 2015, Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial, Lancet Oncol, 16, 1380, 10.1016/S1470-2045(15)00135-7 · DOI · Paper page
  14. Soran, 2016, A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01), J Clin Oncol, 34
  15. Greenberg, 1996, Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer, J Clin Oncol, 14, 2197, 10.1200/JCO.1996.14.8.2197 · DOI · Paper page
  16. Krop, 2014, Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial, Lancet Oncol, 1, 689, 10.1016/S1470-2045(14)70178-0 · DOI · Paper page
  17. Ellis, 2015, Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study, J Clin Oncol, 33
  18. Urruticoechea, 2016, PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting, J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.504 · doi:10.1200/jco.2016.34.15_suppl.504
  19. Kaufman, 2009, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J Clin Oncol, 27, 5529, 10.1200/JCO.2008.20.6847 · DOI · Paper page
  20. von Minckwitz, 2009, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/breast international group 03-05 study, J Clin Oncol, 27, 1999, 10.1200/JCO.2008.19.6618 · DOI · Paper page
  21. Rayson, 2014, Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact, Breast J, 20, 408, 10.1111/tbj.12284 · doi:10.1111/tbj.12284
  22. Tripathy, 2014, The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer, BMC Cancer, 14, 307., 10.1186/1471-2407-14-307 · DOI
  23. Andersson, 2011, Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study, J Clin Oncol, 29, 264, 10.1200/JCO.2010.30.8213 · DOI · Paper page
  24. Burstein, 2007, Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study, Cancer, 110, 965, 10.1002/cncr.22885 · DOI · Paper page
  25. Smyth, 2016, Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study, Breast Cancer Res Treat, 158, 91, 10.1007/s10549-016-3851-7 · DOI
  26. Andersson, 2015, The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis, J Clin Oncol, 33, 586., 10.1200/jco.2015.33.15_suppl.586 · doi:10.1200/jco.2015.33.15_suppl.586
  27. Untch, 2016, Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial, Lancet Oncol, 17, 345, 10.1016/S1470-2045(15)00542-2 · DOI · Paper page
  28. Lobbezoo, 2016, In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium, Ann Oncol, 27, 256, 10.1093/annonc/mdv544 · DOI
  29. Weigel, 1993, Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma, Cancer Res, 53, 3472
  30. Fribbens, 2016, Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer, J Clin Oncol, 34, 2961, 10.1200/JCO.2016.67.3061 · DOI · Paper page
  31. Harbeck, 2016, Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial, Ann Oncol, 27, 1047, 10.1093/annonc/mdw139 · DOI · Paper page
  32. Bachelot, 2012, Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study, J Clin Oncol, 30, 2718, 10.1200/JCO.2011.39.0708 · DOI · Paper page
  33. Pritchard, 2013, Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2, Clin Breast Cancer, 13, 421, 10.1016/j.clbc.2013.08.011 · DOI
  34. Mehta, 2012, Combination anastrozole and fulvestrant in metastatic breast cancer, N Engl J Med, 367, 435, 10.1056/NEJMoa1201622 · DOI · Paper page
  35. Tutt, 2015, TNT: a randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer, Cancer Res, 75, S3
  36. Cortes, 2015, Overall survival (OS) from the phase 2 study of enzalutamide, an androgen receptor (AR) signaling inhibitor, in ar+ advanced triple-negative breast cancer (aTNBC), Eur J Cancer, 51
  37. Bonnefoi, 2016, A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1), Ann Oncol, 27, 812, 10.1093/annonc/mdw067 · DOI · Paper page
  38. Cortes, 2011, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study, Lancet, 377, 914, 10.1016/S0140-6736(11)60070-6 · DOI · Paper page
  39. Kaufman, 2015, Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, 33, 594, 10.1200/JCO.2013.52.4892 · DOI · Paper page
  40. Munzone, 2015, Clinical overview of metronomic chemotherapy in breast cancer, Nat Rev Clin Oncol, 12, 631, 10.1038/nrclinonc.2015.131 · DOI
  41. Stopeck, 2010, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, 28, 5132, 10.1200/JCO.2010.29.7101 · DOI · Paper page
  42. Amadori, 2013, Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial, Lancet Oncol, 14, 663, 10.1016/S1470-2045(13)70174-8 · DOI · Paper page
  43. Hortobagyi, 2014, Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial, J Clin Oncol, 32: 5s
  44. Himelstein, 2015, CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.9501 · doi:10.1200/jco.2015.33.15_suppl.9501
  45. VEJonesLLJensenKJMcIntyre. Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: preliminary results of a randomized phase II study. 2015 San Antonio Breast Cancer Symposium; December 5–8, 2015; San Antonio, TX. Abstract P1-15-06. · doi:10.1158/1538-7445.sabcs15-p1-15-06
  46. Rugo, 2016, Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial, J Clin Oncol, 34, 10.1200/jco.2016.34.26_suppl.189 · doi:10.1200/jco.2016.34.26_suppl.189
  47. Roila, 2016, MASCC and ESMO Consensus Guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: ESMO clinical practice guidelines, Ann Oncol, 27, v119, 10.1093/annonc/mdw270 · DOI · Paper page
  48. Payne, 2012, Interventions for fatigue and weight loss in adults with advanced progressive illness, Cochrane Database Syst Rev, 1, CD008427.
  49. Berger, 2015, Screening, evaluation and management of cancer-related fatigue: ready for implementation to practice, CA Cancer J Clin, 65, 190, 10.3322/caac.21268 · DOI · Paper page
  50. Travier, 2015, Effects of an 18-week exercise programme started early during breast cancer treatment: a randomized controlled trial, BMC Med, 8, 121., 10.1186/s12916-015-0362-z · DOI · Paper page
  51. Koornstra, 2014, Management of fatigue in patients with cancer – a practical overview, Cancer Treat Rev, 40, 791, 10.1016/j.ctrv.2014.01.004 · DOI

Cited by

See all 2,033

Metadata

Authors
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M. J., Pierga, J. Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., & Winer, E.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-01
Volume
28
Issue
1
Pages
16-33
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdw544
OpenAlex
W2560635244
Cited by
2,033
References
47
FWCI
62.84
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). https://app.cochat.ai/papers/10.1093/annonc/mdw544
The paper
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., . . . Winer, E. (2017). 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology. https://doi.org/10.1093/annonc/mdw544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.